



1646

CASE D0075 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico

Type or print name

[Signature]

Signature

6-30-03

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 09/991,225

FILED: NOVEMBER 16, 2001

FOR: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,
HGPRBMY11, EXPRESSED HIGHLY IN HEART AND VARIANTS
THEREOF

MAIL STOP: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
JUL 07 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Some of the listed references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: 6-30-03

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0075 NP
APPLICATION NO.
09/991,225
APPLICANT
FEDER ET AL.
FILING DATE
NOVEMBER 16, 2001

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

RECEIVED
JUL 07 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM	WO9905274	7/23/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Database EMBL Online, October 2, 2000, Retrieved from Database Accession No. AF254664, XP002237607
AS	Heise et al. (2000) J. of Biological Chemistry 275(39)30531-30536
AT	Sarau et al. (1999) Amer. Society for Pharmacology and Exp. Therapeutics 56:657-663

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0075 NP
APPLICATION NO.
09/991,225
APPLICANT
FEDER ET AL.
FILING DATE
NOVEMBER 16, 2001

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Marchese et al. (1999) Genomics 56:12-21
2AB	Stadel et al. (1997) TIPS, Elsevier Science 18:430-437
2AC	Wilson et al. (1998) British J. of Pharmacology 125:1387-1392
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

RECEIVED
JUL 07 2003
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.